Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

BERLIN, Sept. 17, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).  The data were presented in an oral presentation at the International Liver Cancer Association (ILCA) Annual Meeting in Berlin, Germany, by Mong Cho, M.D., from Pusan National University Yangsan Hospital, South Korea.

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intra-tumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

The primary objective of this study was to determine the safety of JX-594 followed by sorafenib in patients with advanced HCC. The sequential treatment regimen was well tolerated with transient flu-like symptoms and transient leukopenia being the most common side effects related to JX-594.  The sorafenib side effects observed were consistent with the expected toxicity profile of this product.

Secondary endpoints included the effect of the sequential treatment of JX-594 followed by sorafenib on disease control and tumor response. Evidence of antitumor activity was observed in both sorafenib-naive and sorafenib-refractory patients. 

Importantly, this trial also demonstrated the feasibility of the systemic administration of the product (through intravenous injection).

"Our ability to deliver JX-594 intravenously to liver cancer tumors, further confirmed by these encouraging data, is a key attribute that sets it apart from other thera
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX,Pharmaceuticals, Inc. (NASDAQ:EPIX) ... executive officer of EPIX, is,scheduled to present at ... Tuesday, July 10, 2007 at 1:30 p.m.,(EDT) at ... The presentation will be webcast live and can ...
... DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.,(NASDAQ:ACCL), the ... announced today that its CFO,Rick Russo, will present ... in New York on July 11, 2007 at,10:30 ... the Mandarin,Oriental Hotel July 10th-12th. In attendance will ...
Cached Medicine Technology:EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference 2Accelrys to Present to Investors at C.E. Unterberg Emerging Growth,Opportunities Conference 2
(Date:4/23/2014)... A novel compound that targets an important brain receptor ... addiction behaviors, including relapse behavior, a University at Buffalo ... evidence that this may be a novel lead compound ... exist., The UB research was published as an online ... In the study, the compound, RO5263397, severely blunted a ...
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... be common in tropical countries along with the ... researchers in Houston, Texas whose study was published in ... available online. ,Staphylococcus aureus, or staph, ... in the nose of a quarter to a third ...
... the caregiver to a 12-year-old autistic boy who fell to ... being charged with the boy's// death. This despite the police ... his death. ,The boy's name has never been ... not say if they were reopening the case or what ...
... potent herbs, has now uncorked a new product: herbal wine. ... Thapa, a resident of tourist town Pokhara in western Nepal, ... ,For many families, alcohol is an integral part of ... local liquors thrive in Nepal's markets along with foreign beers, ...
... between overweight and infertility in women is well known, but ... the case of obese men.//, ,New research has ... that a man’s chances of getting infertile are enhanced by ... during the four years prior to participating in the study ...
... develop symptoms like chest pain or breathlessness almost 2 hours ... death victims were already at a risk as they had ... prevent sudden cardiac death can be made by learning to ... ,"Our study suggests that shifting the focus to educating ...
... often than biologists once thought. Cutting and rearrangement of the ... by// the human cells. ,The immune system of ... could also help researchers understand better how the immune system ... ,Depending on the specific type of protein required, an ...
Cached Medicine News:Health News:MRSA Linked with Rise in Bacterial Infections 2Health News:Nepal Uncorks 'Herbal Wine' 2Health News:Symptoms develop long before the 'Sudden' Cardiac Death 2Health News:'Mix and match' of proteins may have a significant role in immunity 2
Micro suture forceps....
30 Degree angle....
Operating microscope with motorized zoom and variable focus up to 405 mm....
Advanced operating microscope with zoom and variable focus up to 500 mm....
Medicine Products: